Cargando…
Exanthematous Drug Eruption to Intravenous Iron: A Case Report
The authors present a rare case of an exanthematous drug reaction to intravenous iron. Exanthematous drug eruptions, also called morbilliform or maculopapular drug rashes, can occur in first-time drug exposures and represent a subtype of delayed-type IV hypersensitivity reactions. This patient is a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915382/ https://www.ncbi.nlm.nih.gov/pubmed/35340473 http://dx.doi.org/10.7759/cureus.22045 |
_version_ | 1784668009547169792 |
---|---|
author | Mantri, Shilpa S Ballam Nagaraj, Niraj Patel, Chirag Solanki, Kinjal Rana, Haris |
author_facet | Mantri, Shilpa S Ballam Nagaraj, Niraj Patel, Chirag Solanki, Kinjal Rana, Haris |
author_sort | Mantri, Shilpa S |
collection | PubMed |
description | The authors present a rare case of an exanthematous drug reaction to intravenous iron. Exanthematous drug eruptions, also called morbilliform or maculopapular drug rashes, can occur in first-time drug exposures and represent a subtype of delayed-type IV hypersensitivity reactions. This patient is a 49-year-old female with a history of iron deficiency anemia and hypothyroidism who presented to the emergency department after experiencing a diffuse whole-body maculopapular rash following ferumoxytol 510 mg intravenously received once two days prior to her presentation. A clinical examination was suspicious of an exanthematous drug eruption. The patient was treated with methylprednisolone 40 mg intravenously twice a day for three days, followed by prednisone 40 mg orally twice a day for two days with a steroid taper upon discharge. The patient’s rash resolved within five days of steroid treatment. There is a high global prevalence of iron deficiency anemia for which intravenous iron replacement may be required. However, there is limited research addressing its adverse effects, particularly those that include delayed hypersensitivity reactions. This paper aims to alert healthcare professionals of a rare type of delayed hypersensitivity reaction to intravenous iron to better guide management in the clinical setting. |
format | Online Article Text |
id | pubmed-8915382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-89153822022-03-25 Exanthematous Drug Eruption to Intravenous Iron: A Case Report Mantri, Shilpa S Ballam Nagaraj, Niraj Patel, Chirag Solanki, Kinjal Rana, Haris Cureus Internal Medicine The authors present a rare case of an exanthematous drug reaction to intravenous iron. Exanthematous drug eruptions, also called morbilliform or maculopapular drug rashes, can occur in first-time drug exposures and represent a subtype of delayed-type IV hypersensitivity reactions. This patient is a 49-year-old female with a history of iron deficiency anemia and hypothyroidism who presented to the emergency department after experiencing a diffuse whole-body maculopapular rash following ferumoxytol 510 mg intravenously received once two days prior to her presentation. A clinical examination was suspicious of an exanthematous drug eruption. The patient was treated with methylprednisolone 40 mg intravenously twice a day for three days, followed by prednisone 40 mg orally twice a day for two days with a steroid taper upon discharge. The patient’s rash resolved within five days of steroid treatment. There is a high global prevalence of iron deficiency anemia for which intravenous iron replacement may be required. However, there is limited research addressing its adverse effects, particularly those that include delayed hypersensitivity reactions. This paper aims to alert healthcare professionals of a rare type of delayed hypersensitivity reaction to intravenous iron to better guide management in the clinical setting. Cureus 2022-02-09 /pmc/articles/PMC8915382/ /pubmed/35340473 http://dx.doi.org/10.7759/cureus.22045 Text en Copyright © 2022, Mantri et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Mantri, Shilpa S Ballam Nagaraj, Niraj Patel, Chirag Solanki, Kinjal Rana, Haris Exanthematous Drug Eruption to Intravenous Iron: A Case Report |
title | Exanthematous Drug Eruption to Intravenous Iron: A Case Report |
title_full | Exanthematous Drug Eruption to Intravenous Iron: A Case Report |
title_fullStr | Exanthematous Drug Eruption to Intravenous Iron: A Case Report |
title_full_unstemmed | Exanthematous Drug Eruption to Intravenous Iron: A Case Report |
title_short | Exanthematous Drug Eruption to Intravenous Iron: A Case Report |
title_sort | exanthematous drug eruption to intravenous iron: a case report |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915382/ https://www.ncbi.nlm.nih.gov/pubmed/35340473 http://dx.doi.org/10.7759/cureus.22045 |
work_keys_str_mv | AT mantrishilpas exanthematousdrugeruptiontointravenousironacasereport AT ballamnagarajniraj exanthematousdrugeruptiontointravenousironacasereport AT patelchirag exanthematousdrugeruptiontointravenousironacasereport AT solankikinjal exanthematousdrugeruptiontointravenousironacasereport AT ranaharis exanthematousdrugeruptiontointravenousironacasereport |